Artificial Intelligence-assisted Colonoscopy With or Without Endocuff Vision
ConditionAdenoma Detection Rate
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40+
SponsorE-DA Hospital
About this trial
Adenoma detection rate (ADR) is considered the single most important quality measure in colonoscopy and a higher ADR can reduce the risk of interval colorectal cancer (CRC). Several kinds of new endoscopes and accessories have been accessed to investigate the abilities of improving the ADR. Artificial intelligence (AI) and Endocuff vision are promising new devices to improve the ADR. However, the effect of combining AI and Endocuff vision on ADR remains unclear. The aim of this prospective randomized study is to compare the ADR of AI plus Endocuff vision, AI alone and standard colonoscopy examination.
Eligibility criteria
Qualifiers
None
Disqualifiers
A prior history of of inflammatory bowel disease, colorectal cancer, previous bowel resection, Peutz-Jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes
Bleeding tendency
For scheduled endoscopic treatment
Trial design
Treatments tested in this trial
- Artificial intelligence
- Endocuff vision
- High-definition endoscope
Treatment groups
1,000 Participants
are divided into 3 treatment groupsSponsors and collaborators
E-DA Hospital
Lead sponsor
Chung Shan Medical University
Collaborator
Source ClinicalTrials.gov